Stock NAMS FRAZIER LIFESCIENCES ACQUISITION CORPORATION
Add to a list
To use this feature you must be a member
Log inSign up

Company Frazier Lifesciences Acquisition Corporation

Equities

NAMS

NL00150012L7

Biotechnology & Medical Research

Real-time Estimate Tradegate
Other stock markets
 01:30:00 28/06/2024 am IST 		5-day change 1st Jan Change
18.25 EUR -7.59% Intraday chart for Frazier Lifesciences Acquisition Corporation +15.43% +76.81%
11/06 NewAmsterdam Pharma Gets Another US Patent Extending IP Protection for Obicetrapib Until July 2043 MT
10/06 Transcript : NewAmsterdam Pharma Company N.V. Presents at Goldman Sachs 45th Annual Global Healthcare Conference, Jun-10-2024 10:40 AM

Business Summary

NewAmsterdam Pharma Company NV is a Netherlands based company. NewAmsterdam Pharma operates as a clinical-stage company and focuses on the research and development of transformative oral therapies for major cardiometabolic diseases. The Company is investigating obicetrapib, an oral, low-dose and once-daily, cholesteryl ester transfer protein (CETP) inhibitor, as the low-density lipoprotein cholesterol (LDL-C) lowering therapy to be used as an adjunct statin therapy for high-risk cardiovascular disease (CVD) patients. The Company is also testing obicetrapib as a fixed-dose combination therapy with ezetimibe in a secondary Phase 2 trial, ROSE2, for other diseases such as Alzheimer’s disease. The Company strives to offer its products around the world.

Number of employees: 40

Sales per Business

USD in Million2022Weight2023Weight Delta
Transformative Therapies for Cardio-metabolic Diseases
100.0 %
102 100.0 % 15 100.0 % -85.13%

Sales per region

USD in Million2022Weight2023Weight Delta
Italy
100.0 %
102 100.0 % 15 100.0 % -85.13%

Share class

VoteQuantityFree-FloatCompany-owned sharesTotal Float
Stock A 1 89,976,538 84,841,876 ( 94.29 %) 0 94.29 %

Shareholders

NameEquities%Valuation
Frazier Life Sciences Management LP
13.59 %
12,226,943 13.59 % 229 M €
Forbion Capital Partners Management Holding BV
13.15 %
11,831,461 13.15 % 222 M €
Bain Capital Life Sciences LP
11.64 %
10,473,913 11.64 % 196 M €
Viking Global Investors LP
8.918 %
8,024,565 8.918 % 150 M €
RA Capital Management LP
8.739 %
7,864,000 8.739 % 147 M €
AMGEN INC.
5.456 %
4,910,000 5.456 % 92 M €
Morningside Group Ltd.
4.513 %
4,060,923 4.513 % 76 M €
Medicxi Ventures (Jersey) Ltd.
3.189 %
2,869,565 3.189 % 54 M €
Adage Capital Partners GP LLC
2.028 %
1,824,601 2.028 % 34 M €
BVF, Inc.
1.691 %
1,521,948 1.691 % 29 M €
NameEquities%Valuation
Frazier Life Sciences Management LP
-
500,333 - 4 M €
RA Capital Management LP
-
333,333 - 3 M €
Affinity Asset Advisors LLC
-
202,599 - 2 M €
GTS Securities LLC
-
121,150 - 957 085 €
Bain Capital Life Sciences LP
-
100,000 - 790 000 €
Deerfield Management Co. LP (Private Equity)
-
92,787 - 733 017 €
Monashee Investment Management LLC
-
31,189 - 246 393 €
HRT Financial LLC
-
30,321 - 239 536 €
Laurion Capital Management LP
-
16,666 - 131 661 €
Vestcor, Inc.
-
9,632 - 76 093 €

Company contact information

NewAmsterdam Pharma Co. NV

Gooimeer 2-35

1411 DC, Naarden

+31 35 206 2971

http://www.newamsterdampharma.com
address Frazier Lifesciences Acquisition Corporation(NAMS)

Sector

Healthcare
Pharmaceuticals & Medical Research
Biotechnology & Medical Research
Biotechnology & Medical Research
Bio Therapeutic Drugs

Sales per region

Ratings for Frazier Lifesciences Acquisition Corporation

Trading Rating
Investor Rating
ESG Refinitiv
More Ratings

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
8
Last Close Price
18.49 EUR
Average target price
35.19 EUR
Spread / Average Target
+90.31%
Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

1st Jan change Capi.
FRAZIER LIFESCIENCES ACQUISITION CORPORATION Stock Frazier Lifesciences Acquisition Corporation
+76.81% 177.72Cr
VERTEX PHARMACEUTICALS INCORPORATED Stock Vertex Pharmaceuticals Incorporated
+16.13% 12TCr
REGENERON PHARMACEUTICALS, INC. Stock Regeneron Pharmaceuticals, Inc.
+19.65% 12TCr
ARGENX SE Stock argenx SE
+21.22% 2.66TCr
BIONTECH SE Stock BioNTech SE
-23.84% 1.99TCr
GENMAB A/S Stock Genmab A/S
-17.47% 1.63TCr
WUXI APPTEC CO., LTD. Stock WuXi AppTec Co., Ltd.
-45.95% 1.55TCr
BEIGENE, LTD. Stock BeiGene, Ltd.
-19.28% 1.55TCr
SAREPTA THERAPEUTICS, INC. Stock Sarepta Therapeutics, Inc.
+63.81% 1.48TCr
NEUROCRINE BIOSCIENCES, INC. Stock Neurocrine Biosciences, Inc.
+1.94% 1.37TCr
Bio Therapeutic Drugs
  1. Stock Market
  2. Equities
  3. NAMS Stock
  4. Company Frazier Lifesciences Acquisition Corporation